Alteration of Loperamide-induced Prostate Relaxation in High-fat Diet-fed Rats

Overview

Journal ScientificWorldJournal

Publisher Wiley

Specialty Biology

Date 2014 Dec 16

PMID 25506071

Citations 1

Authors

Sheng-Lung Hsu

Hsien-Hui Chung

I-Hung Chen

Yat-Ching Tong

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the change of loperamide-induced prostate relaxation in rats fed with high-fat diet (HFD).

Materials And Methods: Adult male Wistar rats were divided into 2 groups: (1) control rats fed with normal chow and (2) rats fed with HFD for 6 months. The prostate was removed for histology study. Isolated prostate strips were hung in organ bath and precontracted with 1 μmol/L phenylephrine or 50 mmol/L KCl. The relaxation responses to loperamide 0.1 to 10 μmol/L were recorded. Western blotting analyses were performed for prostate μ-opioid receptors (MOR) and ATP-sensitive potassium (K(ATP)) channel proteins: sulfonylurea receptor (SUR) and inwardly rectifying potassium channel (Kir) 6.2 subunits.

Results: Body weight, prostate weight, plasma levels of glucose, insulin, triglyceride, and cholesterol, as well as systolic blood pressure, were significantly increased in the HFD rats. Histology showed prostatic hyperplasia in the HFD rat prostate. Prostatic relaxation induced by loperamide was markedly reduced in HFD when compared to the control. Protein expressions of MOR, SUR, and Kir 6.2 were decreased in HFD-fed rats.

Conclusion: Loperamide-induced prostate relaxation is decreased in HFD rats due to reduced MOR and K(ATP) channel expressions.

Citing Articles

North-south syndrome in veno-arterial extra-corporeal membrane oxygenator: the other Harlequin syndrome.

St-Arnaud C, Theriault M, Mayette M Can J Anaesth. 2019; 67(2):262-263.

PMID: 31598907 DOI: 10.1007/s12630-019-01501-w.

References

Lee L, Lin C, Chung H, Lin K, Cheng J . Urinary bladder relaxation through activation of opioid μ-receptors induced by loperamide is increased in diabetic rats. Exp Clin Endocrinol Diabetes. 2011; 120(6):323-8. DOI: 10.1055/s-0031-1295473. View

Caine M, Perlberg S, Meretyk S . A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978; 50(7):551-4. DOI: 10.1111/j.1464-410x.1978.tb06210.x. View

di Bosco A, Grieco P, Diurno M, Campiglia P, Novellino E, Mazzoni O . Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors. Chem Biol Drug Des. 2008; 71(4):328-35. DOI: 10.1111/j.1747-0285.2008.00637.x. View

Grundy S, Brewer Jr H, Cleeman J, Smith Jr S, Lenfant C . Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109(3):433-8. DOI: 10.1161/01.CIR.0000111245.75752.C6. View

Corbett A, Henderson G, McKnight A, Paterson S . 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2006; 147 Suppl 1:S153-62. PMC: 1760732. DOI: 10.1038/sj.bjp.0706435. View

Lu C, Chung H, Cheng J . Prostatic relaxation induced by loperamide is mediated through activation of opioid μ-2 receptors in vitro. Exp Ther Med. 2012; 2(2):281-285. PMC: 3440672. DOI: 10.3892/etm.2011.201. View

Mannhold R . KATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev. 2004; 24(2):213-66. DOI: 10.1002/med.10060. View

Chen I, Chung H, Cheng J, Tong Y . Metabolic Syndrome Enhances Prostate Contractility and In Vitro Phenylephrine-induced α1 -Adrenoceptor Protein Expression in the Fructose-fed Rat. Low Urin Tract Symptoms. 2015; 5(3):164-7. DOI: 10.1111/luts.12002. View

Yokoyama O, Mita E, Akino H, Tanase K, Ishida H, Namiki M . Roles of opiate in lower urinary tract dysfunction associated with spinal cord injury in rats. J Urol. 2004; 171(2 Pt 1):963-7. DOI: 10.1097/01.ju.0000105160.72711.83. View

10.

Focarelli B, Ausili E, Tabacco F, Rendeli C . Loperamide cause of prolonged urinary retention after acute gastroenteritis. Eur Rev Med Pharmacol Sci. 2007; 11(1):65-7. View

11.

Pandita R, Pehrson R, Christoph T, Friderichs E, Andersson K . Actions of tramadol on micturition in awake, freely moving rats. Br J Pharmacol. 2003; 139(4):741-8. PMC: 1573893. DOI: 10.1038/sj.bjp.0705297. View

12.

Moul S, McVary K . Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol. 2009; 20(1):7-12. DOI: 10.1097/MOU.0b013e3283336f3f. View

13.

Babenko A, Aguilar-Bryan L, Bryan J . A view of sur/KIR6.X, KATP channels. Annu Rev Physiol. 1998; 60:667-87. DOI: 10.1146/annurev.physiol.60.1.667. View

14.

Rohrmann S, Smit E, Giovannucci E, Platz E . Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond). 2005; 29(3):310-6. DOI: 10.1038/sj.ijo.0802881. View

15.

Vikram A, Jena G, Ramarao P . Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate. 2009; 70(1):79-89. DOI: 10.1002/pros.21041. View

16.

Baker D . Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2008; 7 Suppl 3:S11-8. View

17.

Chen I, Tong Y, Cheng J . Metabolic syndrome decreases tissue perfusion and induces glandular hyperplasia in the fructose-fed rat prostate. Neurourol Urodyn. 2012; 31(4):600-4. DOI: 10.1002/nau.21192. View

18.

Gkonos P, Krongrad A, Roos B . Neuroendocrine peptides in the prostate. Urol Res. 1995; 23(2):81-7. DOI: 10.1007/BF00307937. View

19.

Cheng J, Chen I, Yu B, Tong Y . Loperamide-induced rat prostate relaxation through activation of peripheral µ-opioid receptors. Neurourol Urodyn. 2011; 30(3):468-71. DOI: 10.1002/nau.20936. View

20.

Noordzij M, van Steenbrugge G, van der Kwast T, Schroder F . Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res. 1995; 22(6):333-41. DOI: 10.1007/BF00296871. View